ImmuPharma Plc (IMM.L), the specialist drug discovery and development company, said its key scientific collaboration partner and the inventor of ImmuPharma’s lead compound, Lupuzor has issued a press release confirming the effectiveness of the Lupuzor peptide P140.
Lupuzor is ImmuPharma’s lead compound and potential blockbuster drug for Lupus, a chronic autoimmune disease. Lupuzor has received Special Protocol Assessment and Fast Track Designation from the FDA for a Phase III study.
Click here to receive FREE breaking news email alerts for ImmuPharma plc and others in your portfolio
by RTT Staff Writer
For comments and feedback: editorial@rttnews.comBusiness News